Dante Genomics receives grant for a whole genome sequencing project to measure utility of pharmacogenomics in a real, clinical setting
Dante Genomics, a global leader in genomics and precision medicine, today announced that members of its management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, and Andrea Riposati, CEO of Dante Genomics, will participate in a panel presentation on leveraging omics-based data and analytics to advance precision health to the next level on Thursday, August 11, 2022 at 9:30 AM Eastern Time.
Emirates Post, the official postal operator and leading express provider in the UAE, has partnered with Dante Genomics, a global leader in genomics and precision medicine, to facilitate the availability of advanced genomic services across the UAE in line with the nation’s vision of making healthcare testing accessible to everyone in the country.
Dante Genomics, a global leader in genomics and precision medicine, highlights significant progress made in its drug discovery development program with six drug candidates currently in the Company’s pipeline, applying Dante’s internal siRNA and mRNA technology to rare and common diseases.
Dante Labs, a global leader in genomics and precision medicine, is pleased to announce the Italian Ministry of Economic Development has selected Dante to develop and pilot the first fully-CE-IVD, clinically approved whole genome sequencing (WGS) test for the citizens of Italy to be named the Dante Citizen Test.
Dante Labs, a global leader in genomics and precision medicine, is pleased to announce the company has been selected as the genetic testing provider for Abu Dhabi Stem Cells Center (ADSCC).
Dante Labs, a global leader in genomic information and precision medicine, announces new genomic driven biosimulation and significant progress made to its drug discovery program, demonstrating the value of the Dante Platform.
Dante Labs, a global leader in genomics and precision medicine, announces the establishment of the first of its Medical Genomics Boards, strengthening the Company’s mission and research activity in this new frontier of healthcare, using genomics to promote prevention and treatment.
In a study published in The Journal of Prevention of Alzheimer’s Disease (JPAD) – and co-authored by the Department of Psychiatry and the Behavioral Sciences, and Department of Neurology, Keck
